AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions of claims in the application.

1. (Currently Amended) An antibody ~~obtained by immunizing an animal with polypeptides which comprise an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 1 by deletion, substitution, or addition of 1 or several amino acids, and has fibroblast growth factor 23 activity, which has activity controlling phosphate metabolism or vitamin D metabolism, and is shown by the following (a), (b), or (c):~~

~~(a) an antibody which~~ that is raised against and that recognizes an amino acid sequence that is present between the 180th and the 194th, or between the 237th and the 251st amino acid residues ~~represented by~~ of SEQ ID NO: 1~~;~~

~~(b) an antibody which is produced by a hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268; or~~

~~(c) an antibody which is competitive with the antibody produced by the hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268 upon binding with the polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 1~~.

2. (Original) The antibody of claim 1, which is a monoclonal antibody.

3. (Canceled)

4. (Currently Amended) A pharmaceutical composition, which comprises the antibody of ~~any one of claims 1 to 3~~ claim 1 or 2 as an active ingredient.

5. (Canceled)

6. (Currently Amended) The pharmaceutical composition of claim [[5]] 4, which is effective against at least one disease selected from the group consisting of X-linked hypophosphatemic rickets, ~~tumor-induced osteomalacia, XLH,~~ hypophosphatemia,

osteoporosis, ~~disorder of bone extension, disorder of bone calcification, and osteomalacia~~ and renal failure.

7. (Canceled)

8. (Withdrawn – Currently amended) The pharmaceutical composition ~~of any one of claims 4 to 6~~ according to claim 4 or 6, which comprises at least 2 types of the antibodies of claim 1 recognizing different sites.

9. (Canceled)

10. (Withdrawn) A method for detection of a fibroblast growth factor-23, which comprises causing an antibody that recognizes a part of an amino acid sequence between the 25th and the 179th amino acid residues represented by SEQ ID NO: 1 and an antibody that recognizes a part of an amino acid sequence between the 180th and the 251st amino acid residues represented by SEQ ID NO: 1 to react with a test sample.

11. (Withdrawn) The method for detection of claim 10, wherein the antibody that recognizes a part of an amino acid sequence between the 180th and the 251st amino acid residues represented by SEQ ID NO: 1 is an antibody that recognizes an amino acid sequence between the 180th and the 196th amino acid residues represented by SEQ ID NO: 1.

12. (Withdrawn) The method for detection of claim 10, which uses a thrombin inhibitor.

13. (Withdrawn) The method for detection of claim 10 or 11, wherein the antibody is produced by a hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268.

14. (Withdrawn) A kit for detecting a fibroblast growth factor-23, which contains an antibody that recognizes a part of the amino acid sequence between the 25th and the 179th amino acid residues represented by SEQ ID NO: 1 and an antibody that recognizes a part of the amino acid sequence between the 180th and the 251st amino acid residues represented by SEQ ID NO: 1.

15. (Withdrawn) The kit of claim 14, wherein the antibody that recognizes a part of the amino acid sequence between the 180th and the 251st amino acid residues represented by SEQ ID NO: 1 is an antibody that recognizes the amino acid sequence between the 180th and the 196th amino acid residues represented by SEQ ID NO: 1.

16. (Withdrawn) The kit of claim 14 or 15, wherein the antibody is produced by a hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268.

17. (Withdrawn – Currently Amended) An anti-fibroblast growth factor-23 antibody-binding material, to which at least one antibody selected from the antibodies ~~of claims 1 to 3~~ according to claim 1 or 2 is bound.

18. (Withdrawn) A medical appliance, which is provided with the binding material of claim 17.

19. (Withdrawn) The medical appliance of claim 18, which is used for removing the fibroblast growth factor-23 in blood.

20. (New) An antibody produced by a hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268.

21. (New) A pharmaceutical composition, which comprises the antibody of claim 20 as an active ingredient.

22. (New) The pharmaceutical composition of claim 21, which is effective against at least one disease selected from the group consisting of X-linked hypophosphatemic rickets, hypophosphatemia, osteoporosis and renal failure.

23. (New) An antibody which is competitive with the antibody produced by a hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268 upon binding with the polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 1.

24. (New) A pharmaceutical composition, which comprises the antibody of claim 23 as an active ingredient.

25. (New) The pharmaceutical composition of claim 24, which is effective against at least one disease selected from the group consisting of X-linked hypophosphatemic rickets, hypophosphatemia, osteoporosis and renal failure.